APOA1 and breast cancer: The second panel has been proposed to encompass 106 peptide biomarkers (including identified ADAM22, ADAMTS1, Apolipoprotein A-1 (APOA-1), collagen fragments and HSPG2) allowing the detection of BC recurrences with 87% sensitivity and 51% specificity [197].